Join Growin Stock Community!

Hutchmed (china) limitedHCM.US Overview

US StockHealthcare
(No presentation for HCM)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

HCM AI Insights

HCM Overall Performance

HCM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HCM Recent Performance

-2.93%

Hutchmed (china) limited

0.05%

Avg of Sector

-0.31%

S&P500

HCM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

HCM Key Information

HCM Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

HCM Profile

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Price of HCM

HCM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HCM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.13
PE Ratio (TTM)
5.41
Forward PE
-
PS Ratio (TTM)
4.30
PB Ratio
2.00
Price-to-FCF
38.62
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-17.36%
Net Margin
3.68%
Revenue Growth (YoY)
6.26%
Profit Growth (YoY)
-215.95%
3-Year Revenue Growth
-7.05%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.13
PE Ratio (TTM)
5.41
Forward PE
-
PS Ratio (TTM)
4.30
PB Ratio
2.00
Price-to-FCF
38.62
Gross Margin
-17.36%
Net Margin
3.68%
Revenue Growth (YoY)
6.26%
Profit Growth (YoY)
-215.95%
3-Year Revenue Growth
-7.05%
3-Year Profit Growth
-%

  • When is HCM's latest earnings report released?

    The most recent financial report for Hutchmed (china) limited (HCM) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HCM's short-term business performance and financial health. For the latest updates on HCM's earnings releases, visit this page regularly.

  • Where does HCM fall in the P/E River chart?

    According to historical valuation range analysis, Hutchmed (china) limited (HCM)'s current price-to-earnings (P/E) ratio is 6.09, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much debt does HCM have?

    As of the end of the reporting period, Hutchmed (china) limited (HCM) had total debt of 93.44M, with a debt ratio of 0.05. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does HCM have?

    At the end of the period, Hutchmed (china) limited (HCM) held Total Cash and Cash Equivalents of 110.72M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.